

## Review

# Tranexamic Acid Use In Cardiac Surgery: A Review On Indications, Dosage, And Complications

Sohrab Negargar<sup>1\*</sup>

1. Professor Of Anesthesiology And Critical Care, Cardiovascular Research Centre Of Tabriz University Of Medical Sciences, Tabriz, Iran.

**\*Corresponding Author:** Sohrab Negargar, Professor of Anesthesiology and critical care, cardiovascular Research Centre of Tabriz University of Medical Sciences, Tabriz, Iran. Email: negargars@yahoo.com. Orcid: <https://orcid.org/0000-0002-2228-8370>.

## Abstract

It has been demonstrated that cardiovascular diseases are one of the most common causes of death in humans; therefore, various prevention and treatment measures are being taken by the medical community in this regard. For a long time, various treatments have been recommended, including surgeries, but these methods may have a number of complications that the most important of which is bleeding after surgery. Therefore, preserving a patient's blood during heart surgery is very important. Due to the high number of patients undergoing heart surgery and the high probability of using blood products, regardless of the costs to be paid, there is a wide range of known and unknown and at the same time unwanted complications and conditions that can be caused by blood transfusions. Therefore, researchers have conducted several studies to find ways to preserve the blood of patients undergoing heart surgery, including the use of drugs such as tranexamic acid (TXA). TXA is a synthetic analog of the amino acid lysine and an anti-fibrinolytic compound that competitively inhibits plasminogen-to-plasmin activation. This compound non-competitively blocks plasmin at high concentrations, thus TXA prevents the dissolution and destruction of fibrin clots by plasmin. An extensive review of literature has shown that TXA has prevented bleeding in multiple trials without increasing the risk of thrombosis and has a wide range of clinical uses. Despite the role of tranexamic acid in reducing postoperative bleeding, however, the use of this drug will have several side effects. Due to the contradictory results of different literature related to the use of this drug in reducing bleeding and also reducing the need for blood transfusion in patients undergoing surgery, the present review study was conducted to investigate the literature on this subject.

**Keywords:** Tranexamic acid, cardiac surgery, antifibrinolytic agents, blood conservation.

Submitted: 12 November 2021, Revised: 14 December 2021, Accepted: 23 December 2021

## Introduction

Cardiovascular diseases are the most common cause of death in patients which endanger the life of thousands of patients every year [1]. It is estimated that one in three adults in the United States has one or more cardiovascular diseases [2]. According to statistics released by the World Health Organization and the Center for Disease Control and Prevention in 2008, about 17.3 million people died worldwide from these diseases, which it accounts for a 30 percentage of all deaths, and half of them have coronary artery disease [3]. Global statistics show that about 52% of deaths in the United States and 48% in Europe are due to these diseases [4]. It is also predicted that by 2030, about 23.6 million people will die from cardiovascular disease [5]. These diseases cause many problems for patients and high costs for society. Due to the importance of the subject, various methods are used in the treatment of cardiovascular diseases, one of which is surgery, which leads to a reduction in mortality from this disease [6]. About 60% of patients suffering from coronary artery disease undergo surgery [7].

Most patients who undergo heart surgery are uncomplicated in the hospital, but heart surgery has many risks [8]. This surgical method, like all surgical methods, has a number of complications, the most important of which is bleeding after surgery [9]. Due to the high number of patients undergoing heart surgery and the high probability of using blood

products, regardless of the costs to be paid, there is a wide range of complications and conditions related to blood transfusion. Therefore, researchers have conducted several studies in order to find ways to preserve the blood of patients undergoing heart surgery, including the use of drugs such as aminocaproic acid, aprotinin and tranexamic acid [10-12]. There is disagreement in the literature on the use of Tranexamic Acid (T.A.) to prevent bleeding. Some researchers believe in using this drug to reduce bleeding and reduce the need for blood transfusions, and some suggest other drugs.

## Search strategy

We conducted a review study using Google Scholar, MEDLINE / PubMed and Scopus databases to search for relevant trials, till April, 2021. The search was performed using different combination of keywords including Tranexamic acid, cardiac surgery, antifibrinolytic agents, fibrin modulating agents, hemorrhage, bleeding, and blood conservation. No language or template restrictions were used on the search. Additionally, the bibliography of retrieved papers was also examined to identify other relevant publications. A total of 189 studies were identified, which of them 65 studies were considered and summarized related to this study. Issues related to Tranexamic acid use in cardiac surgery including mechanisms of action, indications, dosage, administration and complications investigated in this study. We

first review the mechanisms of action and then the usage and efficacy, dosage, risk factors, indications and adverse effects associated with this antifibrinolytic agent.

### **Cardiac surgery: bleeding and blood transfusion**

Bleeding in patients can be the result of a variety of factors, including surgery, trauma, complications of obstetrics and gynecology, and impaired blood clotting. Meanwhile, bleeding in cardiovascular surgery is a major complication that prolongs hospital stay, increases the need for blood transfusions, and leads to overall mortality from complications such as thrombotic events and stroke [13]. The first complication in cardiac surgery is hemorrhage and is actually 15-20% of the use of blood products in the United States in cardiac surgery [14]. In general, blood loss and subsequent transfusions are associated with major complications and mortality [15, 16]. Coronary artery bypass grafting (CABG) surgery requires different amounts of blood [17]. Up to 90 million units of red blood cells are injected annually worldwide [18]. According to the Adult Cardiac Surgery Database (ACSD), 92.8% of blood use is allocated to coronary surgery [19]. Also, the rate of blood transfusion in a study in 13 CABG centers in 2020 has been reported from 10.9 to 59.9% [20].

It seems that the main cause of bleeding is impaired platelet function and coagulation

factors due to contact of the patient's blood with the cardio-pulmonary pump (CPP) [21, 22]. Abnormal bleeding in CABG surgery has been reported to be 2-5% [23]. Also in studies, about 3% of patients need to reoperation due to heavy bleeding [24]. Finally, preserving patient's blood during heart surgery is very important. Because increased bleeding from surgery is associated with an increased risk of cardiac tamponade, the need for blood transfusions, reoperation of the heart, increased hospital and patient costs, and ultimately increased morbidity and mortality. Therefore, due to the variety of causes of bleeding, it is necessary to use anti-fibrinolytic drugs, which are often used for this purpose.

Over the years, the use of drugs to reduce bleeding in cardiac surgery patients has become very popular. The use of anti-fibrinolytic drugs can reduce blood loss in heart surgery and non-surgical diseases. Evidence of their effectiveness has been increasing for years [25, 26]. One of these drugs is tranexamic acid for use in patients undergoing heart surgery [11]. Some studies have reported that tranexamic acid significantly reduces blood loss, thereby reducing the need for blood transfusions [27-29]. On the other hand, some studies have concluded that the administration of tranexamic acid has no effect on postoperative bleeding [30, 31]. In one study, preoperative use of TXA in patients at risk for bleeding under coronary artery bypass grafting was associated with a reduction in bleeding

without a detectable increase in thrombotic complications within 30 days after surgery compared with placebo [32]. The results of the above study showed that postoperative thrombotic events, blood transfusion needs and reoperation due to major bleeding or cardiac tamponade were significantly reduced in the TXA group. However, postoperative seizures were higher in those who received TXA (0.7% vs. 0.1%, initial trial dose was 50 mg / kg IV). Recently, the results of an extensive meta-analysis by Yao et al. [33] showed that TXA injection significantly reduced postoperative bleeding volume in adult and pediatric patients and in a variety of surgical procedures. The results of this study also showed that TXA significantly reduced the volume of red blood cell (RBC) transfusion [33].

### **Tranexamic acid: mechanism of action**

Synthetic antifibrinolytics such as tranexamic acid (TXA, trans-4- aminomethylcyclohexane-1-carboxylic acid) and Epsilon Aminocaproic Acid ( $\epsilon$  ACA) are analogue of lysine [1]. These agents, first described by S. Okamoto in 1957, bind to plasminogen and plasmin and inhibit fibrinolysis by blocking lysine binding sites on plasminogen molecules [34]. Thus, inhibition of plasminogen activation leads to stabilization of the fibrin network already made by secondary homeostasis (this improves clot formation, stability, and duration) [13]. Tranexamic acid is available in intravenous and oral formulations. Oral and intravenous TXA bioavailability has been reported to be 33 –

34% [35]. Tranexamic acid is six to 10 times stronger and has a longer half-life than  $\epsilon$ - ACA [36]. For intravenous TXA, a half-life of about 2 hours has been reported in healthy volunteers [13]. Removal of the intravenous form of TXA is approximately 90% over a 24-hour period, which is the major excretion mechanism through renal clearance [37, 38]. TXA has been shown to increase thrombosis formation in a dose-dependent manner in animal models [39]. Evidence from several studies suggests that TXA inhibits plasmin-induced platelet activation in extracorporeal flow, such as cardiopulmonary bypass (CPB) used in cardiac surgery [40].

There are several factors that lead to bleeding following CPB, and fibrinolysis is one of the few that can be reduced with medication. TXA also reduces excessive bleeding after CPB by several other mechanisms [41]. 1) The interaction of plasmin and platelets leads to the selective release of ADP granules from platelets, which is caused by contact of the platelet surface with the extracorporeal circulation [42]. 2) TXA may reduce the inflammatory response and associated hemodynamic instability in patients with CPB [43]. 3) Hyperfibrinolysis helps to coagulation disorders in trauma [44]. 4) There are beneficial interactions of TXA with desmopressin, which significantly reduces the blood loss and blood transfusion [45].

**Table 1.** Review on Selected articles on Tranexamic acid

First Author/ year	Indications	Study/Dose/Administration time	Important findings	Ref.
Yao/2020	cardiac surgery	Systematic review and meta-analysis	TXA significantly reduced post-operative blood loss and transfusion requirement	33
Besser/2020	Cardiac Surgery	D-dimer levels: 0.5-5.0 mg/L	A decrease or increase in D-dimer levels during surgery was influenced significantly by a higher or lower tranexamic acid dose	73
Cai/2019	Clinical	Overview	TXA is a non-specific hemostatic agent with numerous clinical uses.	13
Beverly/2019	cardiac surgery	Systematic review and network metaanalysis	TXA improves clot formation, stability, and duration.	74
Gerstein/2018	CardiacSurgery	-	TXA's use in cardiac surgery reduces bleeding risk without a Concomitant increase in thromboembolic complications or an increase in mortality.	72
Myles/2017	coronary artery surgery	100 mg/kg IV (later 50 mg/kg) of body weight administered >30 min after the induction of anesthesia	Moderate—Largely doubleblinded study with good outcomes with perioperative care	32
Yang/2017	Valve replacement surgery	10-15 mg/kg iv	Reduced postoperative bleeding and blood transfusion.	75
Negargar/2016	coronary artery bypass graft surgery	pre and post-pump tranexamic acid	Pre-pump administration of TA had a similar result with post-pump TA administration in terms of bleeding during surgery and need for transfusion	71
Ng /2015	Clinical	Review	TXA is an antifibrinolytic treatment applied in a perioperative setting	41

In general, TXA suppresses fibrinolysis, which is manifested by a decrease in serum D-dimer levels but does not affect the results of

serum blood coagulation markers. In addition, co-administration of heparin does not affect

TXA activity and makes it a useful drug in heparinized patients [46].

### Various indications for TXA

The indications of TXA are very diverse and the most important ones are presented here. Since 2006, anti-fibrinolytic selection in cardiac surgery has changed from aprotinin to TXA and  $\epsilon$ -ACA due to concerns that aprotinin may be associated with an increased risk of heart or brain complications as well as renal failure [47]. Mangano et al. [47] reported that aprotinin is related to increase mortality compared to control, TXA and  $\epsilon$ -ACA. The main purpose of using TXA is to reduce postoperative bleeding and the need for blood transfusion in cardiac and non-cardiac surgeries [16]. There are clear benefits in this regard, both in terms of mortality and in terms of economic costs. In a recent meta-analysis, there is strong evidence that TXA reduces the risk of blood transfusions by 38% [48]. Similarly, a study of the effect of antifibrinolytics on blood loss and blood transfusion showed that TXA significantly reduced blood transfusion by 39%, indicating an absolute risk reduction (ARR) of 18%. However, TXA was not associated with a reduction in mortality in all surgeries [25]. The effect of TXA in major pediatric surgery is the same as that found in the adult population. A study [49] of pediatric patients undergoing cardiac surgery showed that TXA significantly reduced blood loss and reduced blood transfusion during surgery as well as within 48

hours. A systematic review [50] concluded that in pediatric spinal surgery, TXA reduces blood loss and the need for blood transfusions. Basta et al. [51] conducted a systematic review and found that antifibrinolytics reduce blood loss and volume of transfusions, especially in cranial and facial surgery.

Other indications for TXA are including orthopedic surgery, topical use, trauma, neurosurgery, etc. Reducing blood loss is very important in orthopedic surgeries, especially in hip or knee arthroplasty and spine surgery. The use of anti-fibrinolytics in orthopedic surgery is supported by a meta-analysis by Kagoma et al. [52], which showed a reduction in blood loss and a relative risk of blood transfusion. The results of a large retrospective analysis by Poeran et al. [53] showed that patients receiving TXA had lower blood transfusions, fewer thromboembolic events, acute renal failure and comorbidities. In a study by Zhang et al. [54], intra-articular injection of TXA in knee arthroplasty reduced blood loss (396 ml) and reduced the risk of blood transfusion (15.4%). The use of TXA in trauma is supported by strong clinical evidence [55, 56]. Extensive studies have examined other indications of TXA [13, 41].

### Dosage and Complications:

Different doses of tranexamic acid have been suggested in various studies [57]. In previous cardiac surgery studies, the initial trial dose of TXA was reduced from 100 mg / kg IV to 50



mg / kg due to seizures during the postoperative period [58]. Similarly, based on previous studies, a prospective cohort study performed in 8929 patients showed that a dose of TXA greater than 100 mg / kg was independently associated with an increased risk of seizures [59]. The results of a retrospective cohort analysis of 11,529 patients with a history of cardiopulmonary bypass surgery showed that seizures was a significant outcome, especially in patients with risk factors such as age, preoperative neuropathy, and cardiovascular disease [60]. According to these results a few centers use moderate or high dose of TXA because of seizure activity. The occurrence of such complications is associated with renal dysfunction. TXA excreted through the kidneys with case reports showing that the patient treated with TXA increased myoclonic motility with increasing periods of general seizures [37, 38]. In a retrospective analysis of 12,000 patients undergoing cardiopulmonary bypass surgery, low-dose TXA was associated with a lower incidence of seizures [61]. Further documentation on the reduction of seizures in the use of low-dose TXA is shown in an extensive meta-analysis in 2019 [62]. Reducing the dose of TXA ensures a reduction in seizures after heart bypass surgery. Dose reduction in oral and intravenous formulations should be performed depending on serum creatinine measurements [13].

Despite recent pharmacokinetic studies in the pediatric population, the ideal dose of TXA in

pediatric heart surgery is still unknown [63, 64]. In vitro studies in neonates have shown that plasma concentrations are significantly lower (6.5 µg / ml vs. ~ 17 µg / ml), which is required to prevent hyperfibrinolysis compared to adults [64]. The use of TXA antifibrinolytics prescribed at doses between 10 - 15 mg / kg in orthopedic surgery was reported in a meta-analysis and also reported that increasing the TXA dose (no, <1 g, 2 g and 3 g <), was related to decreased the risk of blood transfusion, however the risk of complications did not increase significantly [41]. The results of a meta-analysis [65] show that the use of 2 g < of topical TXA leads to a significantly lower blood transfusion requirement. The use of tranexamic acid during anesthesia in cardiac surgery did not cause any particular side effects [29].

Recently, a TXA dose-response relationship has been suggested as a modifiable risk factor for seizures in patients undergoing heart surgery [66]. It is now clear from the current literature that moderate to high doses of TXA in cardiac surgery are associated with an increased risk of seizures [66, 67]. Sharma et al. [68], with multivariate analysis of more than 11,000 patients after cardiac surgery, reported that TXA was an independent and robust predictor of the development of generalized postoperative seizures. In addition, patients with seizures had a 2.5-fold higher mortality rate. There are different dose ranges for different uses as indicated by clinical trials.

Dowd et al [70] recommended the following dose to achieve complete inhibition of fibrinolysis in cardiac surgery: a loading dose of 30 mg per kg, maintenance infusion at 16 mg per kg per h with an additional 2 mg per kg in the circuit). In general, cumulative evidence suggests that TXA is a tolerable drug that is administered orally, intravenously, or topically. Gastrointestinal disorders, skin allergic reactions, visual disturbances are more common and seizures are less likely to occur at high concentrations [39].

#### Summary of studies related to the use of TXA

TXA has a strong pharmacological and clinical context as an anti-fibrinolytic therapy used in surgery. Administration of TXA should be based on clinical judgment, with guidance on patient history, thromboelastometry, laboratory and radiological examinations, and appropriate to the treatment site and intervention and injection capacity. A review of the literature shows that TXA prevents bleeding in many clinical cases without increasing the risk of thrombosis and has a wide range of clinical applications. Extensive studies have summarized the results of use and therapeutic doses [13, 33, 41], the recent studies in this regard are presented in Table 1. In our previous study (by Negargar et al. [71] using a dose of 20 mg/kg of TA (Tranexamic Acid) pre and post-pump, investigated the effects of TXA on bleeding after coronary artery bypass graft surgery. Our results indicated that administration of TXA before

cardiopulmonary bypass does not lead to a reduction in the need for transfusion as compared to the post-pump administration of TXA [71]. It is difficult to draw definitive conclusions about the clinical application of TXA in conditions that have not been well studied. The risk of thrombosis is a major concern in the use of TXA, although a recent meta-analysis concluded that thrombosis was not significantly increased by TXA [62]. The most prominent associated side effect is seizures. So that high rate of seizures lead to a reduction in the dose of TXA in coronary artery bypass graft surgery. However, seizures was uncommon at doses used in most clinical scenarios [32]. The proposed mechanism which TXA leads to seizures is not understood fully but probably involves the TXA molecule acting on hippocampal  $\gamma$ -amino butyric acid type A and glycine receptors (common antiepileptic therapy targets) in a disinhibiting manner [72]. Due to the contradictory results of various studies on the use of this drug in reducing bleeding as well as reducing the need for blood transfusions in patients undergoing surgery, it is recommended to conduct the extensive studies on the dosage of TXA, the safety and overall efficacy, reduce the risk of seizures and thromboembolism, and review of the results of TXA in new clinical uses.

#### References

1. Stoelting RK, Dierdorf SF. Anesthesia and co-existing disease. 2002.
2. Rosamond, W., Flegel, K., Furie, K., Go, A., Greenlund, K., Haase, N., Hailpern, S.



- M., Ho, M., Howard, V., Kissela, B., Kittner, S., Lloyd-Jones, D., McDermott, M., Meigs, J., Moy, C., Nichol, G., O'Donnell, C., Roger, V., Sorlie, P., Steinberger, J., ... American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2008). Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation*, 117(4), e25–e146. <https://doi.org/10.1161/CIRCULATIONAHA.107.187998>
3. Shafiei Z, Babaee S, Nazari A. Relationship between Mood State and Quality of Life in Patients Undergoing Coronary Artery Bypass Graft Surgery. *IJN*. 2013; 26 (83) :57-67. URL: <http://ijn.iums.ac.ir/article-1-1611-en.html>
  4. Shafiei Z, Babaee S, Nazari A. Relationship between Mood State and Quality of Life in Patients Undergoing Coronary Artery Bypass Graft Surgery. *IJN*. 2013; 26 (83) :57-67. URL: <http://ijn.iums.ac.ir/article-1-1611-en.html>
  5. Mojahed A, Bazi M, Azadi Ahmadabadi C, Abbasi Mendi A, Shahraki N. Comparisons of patients' quality of life before and after coronary artery bypass graft surgery in Ali Ibn Abi Talib Hospital in Zahedan in 2016. *RJMS*. 2018; 25 (3) :1-9. URL: <http://rjms.iums.ac.ir/article-1-4932-en.html>
  6. Babaee G, Keshavarz M, Shayegan AH. Effect of a health education program on quality of life in patients undergoing coronary artery bypass surgery. *Acta Medica Iranica*. 2007;69-75.
  7. MontazerGhaem S, Asar O, Safaei N. Assessing patients' quality of life after open heart surgery in Bandar Abbass, Iran. *Hormozgan Med J* 2012;15(4):254-9.
  8. Newcomb AE, Dignan R, McElduff P, Pearse EJ, Bannon P. Bleeding after cardiac surgery is associated with an increase in the total cost of the hospital stay. *The Annals of thoracic surgery*. 2020 Apr 1; 109(4):1069-78. DOI: 10.1016/j.athoracsur.2019.11.019
  9. Fassin W, Himpe D, Alexander JP, Borms S, Theunissen W, Muylaert P, Van Cauwelaert P. Predictive value of coagulation testing in cardiopulmonary bypass surgery. *Acta Anaesthesiologica Belgica*. 1991 Jan 1; 42(4):191-8.
  10. Casati V, Guzzon D, Oppizzi M, Cossolini M, Torri G, Calori G, Alfieri O. Hemostatic effects of aprotinin, tranexamic acid and ε-aminocaproic acid in primary cardiac surgery. *The Annals of thoracic surgery*. 1999 Dec 1; 68(6):2252-6. DOI: 10.1016/s0003-4975(99)00866-8
  11. Hekmat K, Zimmermann T, Kampe S, Kasper SM, Weber SM, Geissler HJ, Mehlhorn U. Impact of tranexamic acid vs. aprotinin on blood loss and transfusion requirements after cardiopulmonary bypass: a prospective, randomised, double-blind trial. *Current medical research and opinion*. 2004 Jan 1;20(1):121-6. DOI: 10.1185/030079903125002658.
  12. Casati V, Della Valle P, Benussi S, et al. Effects of tranexamic acid on postoperative bleeding and related hematochemical variables in coronary surgery: Comparison between on-pump and off-pump techniques. *J Thorac Cardiovasc Surg*. 2004;128(1):83-91. doi:10.1016/j.jtcvs.2003.10.034
  13. Cai J, Ribkoff J, Olson S, et al. The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients. *Eur J Haematol*. 2020;104(2):79-87. doi:10.1111/ejh.13348
  14. Herbertson M. Recombinant activated factor VII in cardiac surgery. *Blood Coagul Fibrinolysis*. 2004;15 Suppl 1:S31-S32. doi:10.1097/00001721-200405001-00007
  15. Karkouti K, Wijesundera DN, Yau TM, et al. The independent association of massive blood loss with mortality in cardiac surgery. *Transfusion*. 2004;44(10):1453-1462. doi:10.1111/j.1537-2995.2004.04144.x

16. Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. *Transfusion*. 2006;46(3):327-338. doi:10.1111/j.1537-2995.2006.00724.x
17. Kappetein AP, Feldman TE, Mack MJ, Morice MC, Holmes DR, Stähle E, Dawkins KD, Mohr FW, Serruys PW, Colombo A. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. *Eur Heart J*. 2011 Sep;32(17):2125-34. doi:10.1093/eurheartj/ehr213.
18. Flegel WA, Natanson C, Klein HG. Does prolonged storage of red blood cells cause harm?. *Br J Haematol*. 2014;165(1):3-16. doi:10.1111/bjh.12747
19. Bennett-Guerrero E, Zhao Y, O'Brien SM, et al. Variation in use of blood transfusion in coronary artery bypass graft surgery. *JAMA*. 2010;304(14):1568-1575. doi:10.1001/jama.2010.1406
20. Fitzgerald DC, Simpson AN, Baker RA, et al. Determinants of hospital variability in perioperative red blood cell transfusions during coronary artery bypass graft surgery [published online ahead of print, 2020 May 13]. *J Thorac Cardiovasc Surg*. 2020;S0022-5223(20)31128-4. doi:10.1016/j.jtcvs.2020.04.141
21. Khuri SF, Wolfe JA, Josa M, Axford TC, Szymanski I, Assousa S, Ragno G, Patel M, Silverman A, Park M, Valeri CR. Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. *The journal of Thoracic and cardiovascular surgery*. 1992 Jul 1;104(1):94-107.
22. Cramer EM, Lu H, Caen JP, Soria C, Berndt MC, Tenza D. Differential redistribution of platelet glycoproteins Ib and IIb-IIIa after plasmin stimulation [published erratum appears in *Blood* 1991 Jul 15; 78 (2): 545].
23. Fullerton D, Grover F. *Surgery of the chest*. 6 th Ed. Toronto. Saunders Company. 1996; pp: 1884-1897.
24. Branchereau A. *Glenn's Thoracic and Cardiovascular Surgery*. 6th Edn.
25. Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. *The Cochrane Database of Systematic Reviews*. 2011 Jan(1):CD001886. DOI: 10.1002/14651858.cd001886.
26. Ortmann E, Besser MW, Klein AA. Antifibrinolytic agents in current anaesthetic practice. *British journal of anaesthesia*. 2013 Oct 1;111(4):549-63. <https://doi.org/10.1093/bja/aet154>
27. Santos AT, Kalil RA, Bauemann C, Pereira JB, Nesralla IA. A randomized, double-blind, and placebo-controlled study with tranexamic acid of bleeding and fibrinolytic activity after primary coronary artery bypass grafting. *Brazilian journal of medical and biological research*. 2006 Jan;39(1):63-9.
28. Kohno K, Kimura S, Kashima T, Kume M, Hirata I, Amano H, Iwasa S, Meguro T, Fukaya T. Hemostatic effect of tranexamic acid (transamin) during coronary artery bypass grafting. *Journal of Artificial Organs*. 2001 Sep;4(3):241-4.
29. Brown JR, Birkmeyer NJ, O'Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. *Circulation*. 2007 Jun 5;115(22):2801-13.
30. Andreasen JJ, Nielsen C. Prophylactic tranexamic acid in elective, primary coronary artery bypass surgery using cardiopulmonary bypass. *Eur J Cardiothorac Surg*. 2004;26(2):311-317. doi:10.1016/j.ejcts.2004.03.012
31. Ghavidel AA, Jalilifar N, Sharifi M, Ghasemzadeh B, Alinejad Z, Ghafarinejad MH, Khamushi A, Bakhshande H, Hosseini S,

Farsad F, Yousefnia MA. Role of Epsilon Aminocaproic acid & Tranexamic Acid, vs Placebo in Reduction of mediastinal Bleeding following Open Heart Surgery.

32. Myles PS, Smith JA, Forbes A, et al. Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery [published correction appears in *N Engl J Med*. 2018 Feb 22;378(8):782]. *N Engl J Med*. 2017;376(2):136-148.

doi:10.1056/NEJMoa1606424

33. Yao YT, He LX, Tan JC. The effect of tranexamic acid on the values of activated clotting time in patients undergoing cardiac surgery: A PRISMA-compliant systematic review and meta-analysis. *J Clin Anesth*. 2020;67:110020.

doi:10.1016/j.jclinane.2020.110020

34. Roberts I, Shakur H, Coats T, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. *Health Technol Assess*. 2013;17(10):1-79. doi:10.3310/hta17100

35. Callender ST, Warner GT, Cope E. Treatment of menorrhagia with tranexamic acid. A double-blind trial. *Br Med J*. 1970;4(5729):214-216.

doi:10.1136/bmj.4.5729.214

36. Ozier Y, Schlumberger S. Pharmacological approaches to reducing blood loss and transfusions in the surgical patient. *Can J Anaesth*. 2006;53(6 Suppl):S21-S29. doi:10.1007/BF03022249

37. Shakur H, Beaumont D, Pavord S, Gayet-Ageron A, Ker K, Mousa HA. Antifibrinolytic drugs for treating primary postpartum haemorrhage. *Cochrane Database Syst Rev*. 2018;2(2):CD012964. Published 2018 Feb 20. doi:10.1002/14651858.CD012964

38. Sentilhes L, Winer N, Azria E, et al. Tranexamic Acid for the Prevention of Blood Loss after Vaginal Delivery. *N Engl J Med*.

2018;379(8):731-742.

doi:10.1056/NEJMoa1800942

39. McCormack PL. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. *Drugs*. 2012;72(5):585-617. doi:10.2165/11209070-000000000-00000

40. Khuri SF, Valeri CR, Loscalzo J, et al. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. *Ann Thorac Surg*. 1995;60(4):1008-1014. doi:10.1016/0003-4975(95)00668-b

41. Ng W, Jerath A, Wąsowicz M. Tranexamic acid: a clinical review. *Anaesthesiol Intensive Ther*. 2015;47(4):339-350. doi:10.5603/AIT.a2015.0011

42. Soslau G, Horrow J, Brodsky I. Effect of tranexamic acid on platelet ADP during extracorporeal circulation. *American journal of hematology*. 1991 Oct;38(2):113-9.

43. Jimenez JJ, Iribarren JL, Lorente L, et al. Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial. *Crit Care*. 2007;11(6):R117. doi:10.1186/cc6173

44. Schöchl H, Frietsch T, Pavelka M, Jámboř C. Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry. *J Trauma*. 2009;67(1):125-131. doi:10.1097/TA.0b013e31818b2483

45. Ozal E, Kuralay E, Bingöl H, Cingöz F, Ceylan S, Tatar H. Does tranexamic acid reduce desmopressin-induced hyperfibrinolysis?. *J Thorac Cardiovasc Surg*. 2002;123(3):539-543. doi:10.1067/mtc.2002.117281

46. Freeman EW, Lukes A, VanDrie D, Mabey RG, Gersten J, Adomako TL. A dose-response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. *Am J Obstet Gynecol*. 2011;205(4):319.e1-319.e3197. doi:10.1016/j.ajog.2011.05.015

47. Mangano DT, Tudor IC, Dietzel C; Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. *N Engl J Med*. 2006;354(4):353-365. doi:10.1056/NEJMoa051379
48. Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. *BMJ*. 2012;344:e3054. Published 2012 May 17. doi:10.1136/bmj.e3054
49. Giordano R, Palma G, Poli V, et al. Tranexamic acid therapy in pediatric cardiac surgery: a single-center study. *Ann Thorac Surg*. 2012;94(4):1302-1306. doi:10.1016/j.athoracsur.2012.04.078
50. Giordano R, Palma G, Poli V, et al. Tranexamic acid therapy in pediatric cardiac surgery: a single-center study. *Ann Thorac Surg*. 2012;94(4):1302-1306. doi:10.1016/j.athoracsur.2012.04.078
51. Basta MN, Stricker PA, Taylor JA. A systematic review of the use of antifibrinolytic agents in pediatric surgery and implications for craniofacial use. *Pediatr Surg Int*. 2012;28(11):1059-1069. doi:10.1007/s00383-012-3167-6
52. Kagoma YK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, Lim W. Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. *Thromb Res*. 2009;123(5):687-696. doi:10.1016/j.thromres.2008.09.015
53. Poeran J, Rasul R, Suzuki S, et al. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. *BMJ*. 2014;349:g4829. Published 2014 Aug 12. doi:10.1136/bmj.g4829
54. Zhang Y, Fu X, Liu WX, Li YM, Ma XL, Li ZJ. Safety and efficacy of intra-articular injection of tranexamic acid in total knee arthroplasty. *Orthopedics*. 2014;37(9):e775-e782. doi:10.3928/01477447-20140825-53
55. CRASH-2 trial collaborators, Shakur H, Roberts I, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. *Lancet*. 2010;376(9734):23-32. doi:10.1016/S0140-6736(10)60835-5
56. CRASH-2 collaborators, Roberts I, Shakur H, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. *Lancet*. 2011;377(9771):1096-1101.e11012. doi:10.1016/S0140-6736(11)60278-X
57. Armellini G, Vinciguerra A, Bonato R, Pittarello D, Giron GP. Tranexamic acid in primary CABG surgery: high vs low dose. *Minerva Anestesiol*. 2004;70(3):97-107.
58. Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. *Obstet Gynecol*. 2010;116(4):865-875. doi:10.1097/AOG.0b013e3181f20177
59. Weeks A. The prevention and treatment of postpartum haemorrhage: what do we know, and where do we go to next?. *BJOG*. 2015;122(2):202-210. doi:10.1111/1471-0528.13098
60. Carroli G, Cuesta C, Abalos E, Gulmezoglu AM. Epidemiology of postpartum haemorrhage: a systematic review. *Best Pract Res Clin Obstet Gynaecol*. 2008;22(6):999-1012. doi:10.1016/j.bpobgyn.2008.08.004
61. Perel P, Ker K, Morales Uribe CH, Roberts I. Tranexamic acid for reducing mortality in emergency and urgent surgery. *Cochrane Database of Systematic Reviews* 2012, Issue 11. Art. No.: CD010245. DOI:10.1002/14651858.CD010245.

63. Chornenki NLJ, Um KJ, Mendoza PA, et al. Risk of venous and arterial thrombosis in non-surgical patients receiving systemic tranexamic acid: A systematic review and meta-analysis. *Thromb Res.* 2019;179:81-86. doi:10.1016/j.thromres.2019.05.003
64. Goobie SM, Meier PM, Sethna NF, et al. Population pharmacokinetics of tranexamic acid in paediatric patients undergoing craniostomy surgery. *Clin Pharmacokinet.* 2013;52(4):267-276. doi:10.1007/s40262-013-0033-1
65. Yee BE, Wissler RN, Zanghi CN, Feng C, Eaton MP. The effective concentration of tranexamic acid for inhibition of fibrinolysis in neonatal plasma in vitro. *Anesth Analg.* 2013;117(4):767-772. doi:10.1213/ANE.0b013e3182a22258
66. Panteli M, Papakostidis C, Dahabreh Z, Giannoudis PV. Topical tranexamic acid in total knee replacement: a systematic review and meta-analysis. *Knee.* 2013;20(5):300-309. doi:10.1016/j.knee.2013.05.014
67. Kaabachi O, Eddhif M, Rais K, Zaabar MA. Inadvertent intrathecal injection of tranexamic acid. *Saudi J Anaesth.* 2011;5(1):90-92. doi:10.4103/1658-354X.76504
68. Manji RA, Grocott HP, Leake J, et al. Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors. *Can J Anaesth.* 2012;59(1):6-13. doi:10.1007/s12630-011-9618-z
69. Sharma V, Katznelson R, Jerath A, et al. The association between tranexamic acid and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients. *Anaesthesia.* 2014;69(2):124-130. doi:10.1111/anae.12516
70. Fiechtner BK, Nuttall GA, Johnson ME, et al. Plasma tranexamic acid concentrations during cardiopulmonary bypass. *Anesth Analg.* 2001;92(5):1131-1136. doi:10.1097/00000539-200105000-00010
71. Dowd NP, Karski JM, Cheng DC, et al. Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. *Anesthesiology.* 2002;97(2):390-399. doi:10.1097/00000542-200208000-00016
72. Negargar S, Naghipour B, Anvari S, Enamzadeh E, Shiriza-Deh M. EFFECTS OF PRE AND POST-PUMP TRANEXAMIC ACID ON BLEEDING AFTER CORONARY ARTERY BYPASS GRAFT SURGERY. *ACTA MEDICA MEDITERRANEA.* 2016 Jan 1;32:1231-5.
73. Gerstein NS, Deriy L, Patel PA. Tranexamic Acid Use in Cardiac Surgery: Hemostasis, Seizures, or a Little of Both. *J Cardiothorac Vasc Anesth.* 2018;32(4):1635-1637. doi:10.1053/j.jvca.2017.12.001
74. Besser V, Albert A, Sixt SU, et al. Fibrinolysis and the Influence of Tranexamic Acid Dosing in Cardiac Surgery. *J Cardiothorac Vasc Anesth.* 2020;34(10):2664-2673. doi:10.1053/j.jvca.2020.03.040
75. Beverly A, Ong G, Wilkinson KL, Doree C, Welton NJ, Estcourt LJ. Drugs to reduce bleeding and transfusion in adults undergoing cardiac surgery: a systematic review and network meta-analysis. *The Cochrane Database of Systematic Reviews.* 2019 Sep;2019(9). doi:10.1002/14651858.CD013649
76. Yang JM, Zhang C, Li CB, Huang GW, Yu DF. Tranexamic acid application in open heart valve replacement surgery. *Chin J Mod Ope Sur* 2017;21(02):117-20.